Microtubule Dynamics Deregulation Induces Apoptosis in Human Urothelial Bladder Cancer Cells via a p53-Independent Pathway

• Published in: Cancers Vol. 15; no. 14; p. 3730
• Main Authors: Drosos, Yiannis, Konstantakou, Eumorphia G, Bassogianni, Aggeliki-Stefania, Nikolakopoulos, Konstantinos-Stylianos, Koumoundourou, Dimitra G, Markaki, Sophia P, Tsitsilonis, Ourania E, Voutsinas, Gerassimos E, Valakos, Dimitrios, Anastasiadou, Ema, Thanos, Dimitris, Velentzas, Athanassios D, Stravopodis, Dimitrios J
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.07.2023; MDPI
• Subjects: Apoptosis; bladder; Bladder cancer; cancer; Cancer therapies; Cell cycle; Chemoresistance; Clinical trials; CRISPR; Data analysis; DNA damage; DNA repair; Epigenetic inheritance; Epigenetics; Flow cytometry; Genes; Genetic engineering; Genomes; Greece; Health aspects; Information management; Metastases; microtubule; Morbidity; Mortality; Ovaries; p53; p53 Protein; Paclitaxel; Transcriptomics; Tumor proteins; Tumors; Urothelial cancer; Greece; United States > US; Germany; microtubule; paclitaxel; bladder; apoptosis; cancer; urothelium; p53
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers15143730

Bladder cancer (BLCA) is the sixth most common type of cancer and has a dismal prognosis if diagnosed late. To identify treatment options for BLCA, we systematically evaluated data from the Broad Institute DepMap project. We found that urothelial BLCA cell lines are among the most sensitive to microtubule assembly inhibition by paclitaxel treatment. Strikingly, we revealed that the top dependencies in BLCA cell lines include genes encoding proteins involved in microtubule assembly. This highlights the importance of microtubule network dynamics as a major vulnerability in human BLCA. In cancers such as ovarian and breast, where paclitaxel is the gold standard of care, resistance to paclitaxel treatment has been linked to p53-inactivating mutations. To study the response of BLCA to microtubule assembly inhibition and its mechanistic link with the mutational status of the p53 protein, we treated a collection of BLCA cell lines with a dose range of paclitaxel and performed a detailed characterization of the response. We discovered that BLCA cell lines are significantly sensitive to low concentrations of paclitaxel, independently of their p53 status. Paclitaxel induced a G2/M cell cycle arrest and growth inhibition, followed by robust activation of apoptosis. Most importantly, we revealed that paclitaxel triggered a robust DNA-damage response and apoptosis program without activating the p53 pathway. Integration of transcriptomics, epigenetic, and dependency data demonstrated that the response of BLCA to paclitaxel is independent of p53 mutational signatures but strongly depends on the expression of DNA repair genes. Our work highlights urothelial BLCA as an exceptional candidate for paclitaxel treatment. It paves the way for the rational use of a combination of paclitaxel and DNA repair inhibitors as an effective, novel therapeutic strategy.